BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26553061)

  • 1. Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer.
    Paulmurugan R; Bhethanabotla R; Mishra K; Devulapally R; Foygel K; Sekar TV; Ananta JS; Massoud TF; Joy A
    Mol Cancer Ther; 2016 Feb; 15(2):221-31. PubMed ID: 26553061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
    Bhargava-Shah A; Foygel K; Devulapally R; Paulmurugan R
    Nanomedicine (Lond); 2016 Feb; 11(3):235-47. PubMed ID: 26787319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
    Godugu C; Doddapaneni R; Singh M
    Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate.
    Esmaeili F; Ghahremani MH; Ostad SN; Atyabi F; Seyedabadi M; Malekshahi MR; Amini M; Dinarvand R
    J Drug Target; 2008 Jun; 16(5):415-23. PubMed ID: 18569286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
    Wang Y; Yu L; Han L; Sha X; Fang X
    Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
    Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery.
    Wang J; Liu W; Tu Q; Wang J; Song N; Zhang Y; Nie N; Wang J
    Biomacromolecules; 2011 Jan; 12(1):228-34. PubMed ID: 21158381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
    Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C
    J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate receptor alpha targeted delivery of artemether to breast cancer cells with folate-decorated human serum albumin nanoparticles.
    Akbarian A; Ebtekar M; Pakravan N; Hassan ZM
    Int J Biol Macromol; 2020 Jun; 152():90-101. PubMed ID: 32057865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate decorated epigallocatechin-3-gallate (EGCG) loaded PLGA nanoparticles; in-vitro and in-vivo targeting efficacy against MDA-MB-231 tumor xenograft.
    Kazi J; Sen R; Ganguly S; Jha T; Ganguly S; Chatterjee Debnath M
    Int J Pharm; 2020 Jul; 585():119449. PubMed ID: 32464231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
    Lale SV; R G A; Aravind A; Kumar DS; Koul V
    Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxymethyl-β-cyclodextrin conjugated nanoparticles facilitate therapy for folate receptor-positive tumor with the mediation of folic acid.
    Su C; Li H; Shi Y; Wang G; Liu L; Zhao L; Su R
    Int J Pharm; 2014 Oct; 474(1-2):202-11. PubMed ID: 25149123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
    He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
    ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.